ClinicalTrials.gg
SuspendedNCT03513549Updated Nov 16, 2026

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

An observational study in Agitation,Psychomotor, sponsored by Nova Pneuma Inc.. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nova Pneuma Inc. · Observational

How we know

Why this study was suspended
Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and makes it feasible to develop an alternative study design as recommended by FDA.
Updated Nov 16, 2026Reason for stopping updatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Psychomotor Agitation with a site in United States — 8 open to participants now, 14 under way, 4 of them phase 3. Psychomotor Agitation · United States.

Planned enrollment
Largest of 14
10,000 · median 136
Started
2014
with 3 others
Observational
15 of 108
1 open now
Registered
62nd of 108
by date

Among the 108 studies in Psychomotor Agitation with a site in United States, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2014, is one of 15 observational ones, and was the 62nd registered.

Psychomotor Agitation

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

Browse Psychomotor Agitation studies →

Open to participants now

8 of the 108 studies in Psychomotor Agitation with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Psychomotor Agitation with a site in United States, or all of them as a file.
02

Study summary

This postmarketing observational study will evaluate the safety of ADASUVE® in treating patients with agitation associated with schizophrenia or bipolar I disorder.

Read the detailed description

This is a multicenter, prospective, observational study conducted to evaluate the safety of ADASUVE treatment when used in real-world clinical setting in patients with agitation associated with schizophrenia or bipolar I disorder.

The primary objective of the study is to assess the safety of ADASUVE treatment in real-world clinical settings.

The secondary objective of the study is to describe the characteristics of patients, including demographic and baseline characteristics, after administration of ADASUVE treatment in real-world clinical settings.

The study population will consist of a non-randomized cohort of approximately 10000 adult men and women who have agitation associated with schizophrenia or bipolar I disorder (naïve and non-naïve to ADASUVE treatment).

03

Conditions studied

  • Agitation,Psychomotor

Keywords

  • Agitation
  • Schizophrenia
  • Bipolar I disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of a non-randomized cohort of approximately 10000 adult men and women who have agitation associated with schizophrenia or bipolar I disorder (naïve and non-naïve to ADASUVE treatment), as determined by the treating health care provider, and who meet the eligibility criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be included in the study if they meet all of the following criteria:

  1. The patient is a man or woman who is 18 years of age or older at time of enrollment.
  2. The patient is receiving ADASUVE for agitation in a medical or psychiatric emergency setting or in a psychiatric inpatient setting. (Note: Patients with a prior history of treatment with ADASUVE may also be included in the study.)
  3. The patient (or caregiver or legally authorized representative) is willing and able to provide written (and assent, where applicable) after administration of ADASUVE treatment.

Exclusion criteria

Exclusion Criteria:

There are no exclusion criteria for this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Loxapine 10 MG

    ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.

    Drug: Loxapine 10 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluating frequency and nature of adverse events, serious adverse events and respiratory adverse events of special interest (AESIs) after administration of ADASUVE treatment in real-world clinical settings

    Safety will be assessed by evaluating adverse events, serious adverse events, and respiratory AESIs within the study follow-up period after administration of ADASUVE treatment in real-world clinical settings.

    Time frame: 24 hours

Secondary outcomes

  1. Patient demographics

    The secondary measure of this study is patient characteristics, including demographic characteristics, after administration of ADASUVE treatment in real-world clinical settings.

    Time frame: 24 hours

  2. Patient baseline characteristics - medical history

    The secondary measure of this study is patient characteristics, including baseline characteristic of medical history, after administration of ADASUVE treatment in real-world clinical settings.

    Time frame: 24 hours

  3. Patient baseline characteristics - prior medications

    The secondary measure of this study is patient characteristics, including baseline characteristic of prior medications, after administration of ADASUVE treatment in real-world clinical settings.

    Time frame: 24 hours

Other outcomes

  1. Exploratory objective - patient treatment satisfaction

    The exploratory objective of the study is to assess patient perception of effectiveness (ranging from extremely dissatisfied to extremely satisfied), convenience (ranging from extremely inconvenient to extremely convenient), and overall satisfaction (ranging from extremely dissatisfied to extremely satisfied) using a modified Treatment Satisfaction Questionnaire for Medication (TSQM) after administration of ADASUVE treatment in real-world clinical settings. The TSQM is a modified version of the original TSQM version 1.4, a widely used generic measure to assess treatment satisfaction with medication. Scores range from 0 to 100, with higher scores representing higher satisfaction.

    Time frame: 24 hours

07

Study locations

1 site
  • Pharmaceutical Research Associates, Inc
    Raleigh, North Carolina 27612, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2014 (actual). Primary completion is estimated for Feb 2028, 159 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Feb 2027 → Feb 2028 and completion Sep 2027 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
May 1, 2018
StartActual
Nov 4, 2014
Primary completionEst.
Feb 2028was Feb 2027
CompletionEst.
Sep 2029was Sep 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Why stopped
Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and makes it feasible to develop an alternative study design as recommended by FDA.
Nov 16, 2026
Primary completion
Feb 2027→Feb 2028
Nov 16, 2026
Study completion
Sep 2027→Sep 2029
Nov 16, 2026
Sponsor
Alexza Pharmaceuticals, Inc.→Nova Pneuma Inc.
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Why stopped Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and makes it feasible to develop an alternative study design as recommended by FDA.
    Primary completion Feb 2027→Feb 2028
    Study completion Sep 2027→Sep 2029
    Sponsor Alexza Pharmaceuticals, Inc.→Nova Pneuma Inc.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03513549
Lead sponsor
Nova Pneuma Inc.
Collaborators
Pharmaceutical Research Associates
Responsible party
Sponsor
First posted
May 1, 2018
Start date
Nov 4, 2014
Primary completion
Feb 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion